Intermountain selects Gestalt, Hamamatsu for digital pathology
June 10, 2022—Intermountain Healthcare has chosen Gestalt Diagnostics and Hamamatsu Photonics to implement digital pathology across its health care system.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Sarstedt introduces CSF false-bottom tube
June 8, 2022—Sarstedt announced the availability of a false-bottom tube for cerebrospinal fluid with an elevated conical base.
Leica launches Bond-Prime staining platform
May 31, 2022—Leica Biosystems launched Bond-Prime, a high-speed immunohistochemistry and in situ hybridization staining platform.
Bio-Rad launches CFX Duet Real-Time PCR system
May 26, 2022—Bio-Rad Laboratories has launched the CFX Duet Real-Time PCR system to support researchers in developing singleplex and duplex quantitative PCR assays.
BD launches infectious disease molecular Dx platform
May 23, 2022—BD announced the U.S. launch of its fully automated, high-throughput infectious disease molecular diagnostics platform, the BD COR MX.
FDA approves Enhertu for breast cancer
May 18, 2022—Daiichi Sankyo and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the United States for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.
FDA approves Hologic Aptima CMV Quant assay
May 16, 2022—Hologic announced that the FDA approved its Aptima CMV Quant assay to quantify the viral load of cytomegalovirus in patients who have had solid organ or stem cell transplants.
Abbott’s STI assay gets FDA clearance
May 13, 2022—Abbott has received FDA clearance for its Alinity m STI assay.
FDA authorizes Fujirebio test for Alzheimer disease
May 11, 2022—Fujirebio Diagnostics announced that the FDA has granted de novo marketing authorization for its Lumipulse G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test for assessing β-amyloid pathology in patients who are being evaluated for Alzheimer’s disease and other causes of cognitive decline.
BioFire joint infection panel gets de novo authorization
May 9, 2022—BioMérieux’s BioFire joint infection panel has received FDA de novo authorization.